Market growth factors such as increasing adoption of target therapy
over traditional therapy, emergence of biosimilars, increasing demand
for mAbs, high prevalence of cancer. Cancer immunotherapy drugs are
designed to alter or boost the body’s natural immune response to fight
cancer this market is research-driven with a high degree of dependence
on the discovery of molecules that can generate an immune response
against various indications.
According to research report the Cancer Immunotherapy Market is projected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion in 2016, at a CAGR of 14.0%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894
This
report provides a detailed overview of the major drivers, restraints,
challenges, opportunities, current market trends, and strategies
impacting the global cancer immunotherapy market along with the
estimates and forecasts of the revenue and market share analysis.
Key
players in the cancer immunotherapy market include Amgen (U.S.),
AstraZeneca (U.K.), F. Hoffmann-La Roche AG (Switzerland), Bayer AG
(Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.),
Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis
(Switzerland), and Pfizer (U.S.).
• On the basis of applications,
the global cancer immunotherapy market is segmented into lung cancer,
breast cancer, colorectal cancer, melanoma, prostate cancer, head &
neck cancer, and others. The lung cancer segment is expected to grow at
the highest CAGR during the forecast period. The high growth in this
segment can be attributed to the increasing prevalence of this type of
cancer and rising demand for advanced treatment options.
• On the
basis of type, the market has been segmented into monoclonal antibodies,
cancer vaccines, checkpoint inhibitors, and immunomodulators. The
monoclonal antibodies segment is expected to account for the largest
share of the market in 2016, while the checkpoint inhibitors segment is
projected to witness the highest CAGR from 2016 to 2021. The high growth
in this segment is primarily attributed to the high success rate of
these inhibitors.
Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=197577894
Based
on regions, the global Cancer Immunotherapy market is segmented into
North America, APAC, Europe and the Rest of the World (RoW). North
America is expected to account for the largest share of the market
during the forecast period. Growth in this regional segment is driven by
factors such as increase in patient pool, and initiative taken by the
government for the development of Cancer Immunotherapy.
